The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy

Miftahussurur, Muhammad; Putra, Boby Pratama; Yamaoka, Yoshio

doi:10.3390/ph13100276

Cited by 30 publications

(20 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The regimens achieved above 91% cure for those who previously failed eradication treatment. Many (85%) patients received higher doses of amoxicillin (1125 mg t.i.d) and vonoprazan (20 mg t.i.d) than those that had been used amoxicillin (750 mg b.d) and vonoprazan (20 mg b.d) previously 37,38 and could be responsible for the outcomes in those regimens. To our knowledge, our protocol's result is the highest first-line eradication rate and our findings are similar to the previously reported efficacy of vonoprazan-containing therapies for the eradication of H. pylori.…”

Section: Discussionmentioning

confidence: 99%

“…39 Previous reports have shown that when vonoprazan-containing regimens were used in first-line and second-line treatment, eradication rates were between 83%-96% and 72%-96%, respectively. 37,38 In addition, one study reported 100% eradication in 19 patients with two failed therapies before being treated with vonoprazan (20 mg), amoxicillin (750 mg), and rifabutin (150 mg) twice daily for 10 days. 40 In addition to the role of vonoprazan itself, the high efficacy achieved from the vonoprazan-containing therapies reported in this study compared to previously published literature may be due to several other factors including treatment duration, type of antibiotics used along with their relative dosages.…”

Section: Discussionmentioning

confidence: 99%

“…Previous reports have shown that when vonoprazan‐containing regimens were used in first‐line and second‐line treatment, eradication rates were between 83%–96% and 72%–96%, respectively. 37 , 38 In addition, one study reported 100% eradication in 19 patients with two failed therapies before being treated with vonoprazan (20 mg), amoxicillin (750 mg), and rifabutin (150 mg) twice daily for 10 days. 40 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections—Exploratory study

et al. 2021

View full text Add to dashboard Cite

Background Vonoprazan fumarate is a novel potassium‐competitive acid blocker more effective in suppressing acid production than proton pump inhibitors (PPIs) and when combined with antibiotics has been used to eradicate Helicobacter pylori (H. pylori) infection. However, it has not yet been examined in an Australian setting. This study aimed to report on the efficacy and safety of vonoprazan‐containing antibiotic combination therapies in the eradication of H. pylori. Methods A single‐center, exploratory, clinical review of patients 18 years or over, positive for H. pylori on Urea Breath Test (UBT), and/or histopathology who underwent a 10‐day treatment of combination antibiotics plus vonoprazan between January 2017 and September 2019 was conducted. Eleven different combinations of antibiotics that included 2–5 different antibiotics predominantly amoxicillin, rifabutin, levofloxacin, furazolidone, nitazoxanide, and tetracycline were included. The eradication success was based on negative UBT results and/or histopathology results after the treatment. Descriptive statistics were summarized. Results One hundred and fifty‐three patients (Female n = 74, 48%) with a positive for H. pylori were treated with vonoprazan‐containing antibiotic combination therapy during the study period. Of the 153 patients, 48 (31%) had previously failed a PPI‐based H. pylori treatment. Follow‐up was available for 66/153 (43%) patients. In those who completed follow‐up, overall eradication was achieved in 97% (64/66) of patients. In the subgroup of patients treated for the first time, eradication was achieved in 100% (44/44). In those who had failed prior, non‐vonoprazan‐containing treatment, eradication was achieved in 91% (20/22) of patients. Conclusions Vonoprazan‐containing antibiotic therapy is an effective H. pylori eradication treatment. It is capable of achieving 100% efficacy in patients treated for the first time and even 91% efficacy in patients with previous eradication failure. Subsequent studies utilizing a factorial design will be needed to optimize each regimen as most regimens contained more than two antibiotics.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections—Exploratory study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The mechanism of action is different from that of PPIs. Conventional PPIs require 3-5 d to achieve maximal and steady-state gastric acid inhibition, whereas P-CABs increase the intragastric pH to nearly 7 within four hours[ 80 ].…”

Section: Up-to-date Research On H Pylori Therapymentioning

confidence: 99%

Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea

Cho¹,

Jin²

2022

WJCC

View full text Add to dashboard Cite

Helicobacter pylori ( H. pylori ) infection is highly prevalent in East Asia. The overall seroprevalence rate of H. pylori infection is 44.2% in China, 37.6%-43.2% in Japan, and 51.0% in South Korea. H. pylori can cause peptic ulcer disease and gastric cancer. East Asian countries have high rates of gastric cancer (age-standardized incidence rate: 20-30 per 100000). The Kyoto global consensus report emphasized that H. pylori gastritis should be considered the main cause for the development of gastric cancer. H. pylori treatment guidelines in China, Japan, and South Korea have recently been revised according to data from each of those countries. However, emerging antibiotic resistance is an important barrier to H. pylori eradication. The recommended H. pylori treatment regimens differ among those three East Asian countries. In this review, recent guidelines and up-to-date research on H. pylori treatment regimens from China, Japan, and South Korea are discussed.

show abstract

“…Helicobacter pylori (Hp) is a flagellated Gram-negative and spiral-shaped bacterium that is colonized in the stomach, which is one of the most common chronic bacterial infections in humans, affecting approximately 4.4 billion individuals worldwide [ 1 , 2 ]. In China, approximately 50% to 80% of the population is infected with Hp, and the rate is still rising [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

TCM-Based Therapy as a Rescue Therapy for Re-Eradication of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis

Zhong

Liu

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

The increase in drug-resistant strains poses a severe challenge for Helicobacter pylori (Hp) treatment, and the failure of traditional triple or bismuth quadruple therapy makes it difficult to eradicate Hp. Tailored therapies should be expanded, and traditional Chinese medicine (TCM) may provide the potential regimen. The aim of the present study is to systematically compare TCM-based therapy (TCM combined with Western medicine) and Western medicine as a rescue therapy for Hp re-eradication. Studies through June 12, 2021, with keywords “Helicobacter pylori,” “medicine, Chinese traditional,” or “rescue treatment” and their related expressions were retrieved from PubMed, SinoMed, China National Knowledge Infrastructure, and Wanfang databases. Randomized clinical trials based on PICOS (population, intervention, comparators, outcomes, and study design) eligibility criteria that evaluated the efficacy and safety of integrated therapy on Hp re-eradication were included. The extracted contents included the demographic data of the participants, specific treatment measures, and the results of outcome indicators and safety indicators. Review Manager 5.3 software was used to perform this meta-analysis. Outcome measures including the HP re-eradication rate, symptom remission rate, and adverse effects were seriously analyzed. Under the guide of PRISMA, 18 studies were finally included. Pooled results showed significant differences in eradication rate between integrated and Western medicine therapy in intention-to-treat (ITT) analysis (OR = 2.21, 95% CI: (1.74, 2.81), P < 0.01 ). Symptom remission is higher in the administration of integrated therapy than in the administration of Western medicine therapy (OR = 2.45, 95% CI: (1.78, 3.37), P < 0.01 ). It is also indicated that integrated therapy showed significantly less adverse effects (OR = 0.60, 95% CI: (0.42, 0.84), P < 0.01 . In conclusion, compared with Western medicine therapy, integrated therapy yields a higher eradication rate and acceptable safety profiles.

show abstract

The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy

Cited by 30 publications

References 95 publications

Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections—Exploratory study

Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections—Exploratory study

Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea

TCM-Based Therapy as a Rescue Therapy for Re-Eradication of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About